Abstract 503P
Background
In the registrational trials, afatinib (afa) was active against NSCLC tumors harboring common and uncommon EGFR mutations, including G719X, L861Q and S768I,1 and is approved in this setting. Here, we assess 1st-line afa in pts with uncommon EGFR mutations treated in a ‘real-world’ setting in the largest analysis of its kind to date.
Methods
Retrospective pooled analysis of three ‘real-world’ studies: an expanded-access program in Korea (1200.193); an Asian phase IIIB trial (1200.66); a global phase IIIB trial (mainly Europe; 1200.55). Pts had EGFR mutation-positive (EGFRm+) NSCLC, were EGFR TKI-naïve, and received afa 40 mg/day. Dose reduction was permitted (minimum 20 mg/day). Endpoints included time to symptomatic progression (TTSP), investigator-assessed PFS and ORR.
Results
Overall, 1108 pts were treated with afa: median age, 61 yrs; female, 58%; ECOG PS of 0/1/2, 26%/70%/4%; asymptomatic brain metastases, 19%; 1st-line afatinib, 69%. 198 (18%) had tumors harboring at least one uncommon mutation (exon 20 insertions [Ins20]: n = 70; T790M: n = 20; G719X: n = 41; L861Q: n = 47; S768I: n = 20; other: n = 25. Of note, 35% of pts had Ins20 mutations, a heterogeneous group generally resistant to EGFR TKIs). Median TTSP, PFS and ORR were 8.3 mos (95% CI 7.2–11.0), 7.4 mos (95% CI 6.0–9.0) and 37% respectively. Median duration of response was 10.2 mos (95% CI 8.4–12.9). In those pts with uncommon mutations and brain metastases, median TTSP and PFS were 7.6 mos (95% CI 4.6–10.1) and 7.4 mos (95% CI 4.6–9.1). Clinical activity in pts with uncommon mutations was greatest against tumors harboring G719X, L861Q or S768I. Some pts with Ins20 or T790M mutations appeared to benefit from treatment. Survival data in specific mutation subgroups will be presented.
Conclusions
In this ‘real-world’ analysis, nearly 20% of pts with EGFRm+ NSCLC harbored uncommon EGFR mutations. Afa was active in a broad range of these pts, including some with Ins20 mutations. 1. Yang, JC. et al. Lancet Oncol 2015;16:830–8.
Table: 503P
EGFR mutation type | ||||||
---|---|---|---|---|---|---|
Common | Uncommon | |||||
Del19 | L858R | T790M | Ins20 | T790M + Ins 20 | G719X, L861Q, S768I and Other | |
n | 531 | 378 | 15 | 65 | 5 | 113 |
Median TTSP, mos (95% CI) | 17.2 (15.5, 19.3) | 14.5 (13.1, 16.5) | 8.2 (2.7, 13.4) | 5.9 (3.8, 8.2) | 1.5 (0.1, 13.0) | 11.0 (9.0, 16.4) |
Median PFS, mos (95% CI) | 14.5 (13.8, 15.9) | 12.6 (11.1, 13.8) | 7.1 (2.0, 9.0) | 5.6 (3.9, 7.4) | 1.5 (0.1, 9.1) | 9.2 (7.3, 12.1) |
ORR, % | 64 | 52 | 20 | 23 | 20 | 49 |
Median DOR, mos (95% CI) | 14.1 (12.6, 16.2) | 12.5 (11.1, 14.9) | 12.5 (1.1, 12.5) | 10.1 (3.7, 21.2) | 8.3 (NE, NE) | 10.2 (8.3, 15.5) |
Clinical trial identification
NCT01931306; NCT01953913; NCT01853826.
Editorial acknowledgement
Lynn Pritchard of GeoMed, an Ashfield company, part of UDG Healthcare plc.
Legal entity responsible for the study
Boehringer Ingelheim.
Funding
Boehringer Ingelheim.
Disclosure
F. De Marinis: Honoraria (self): Roche; Honoraria (self): AstraZeneca; Advisory / Consultancy: Takeda; Research grant / Funding (institution): Boehringer Ingelheim. V. Lee: Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self): Eli Lilly; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Merck Sharp & Dohme. L. Clementi: Full / Part-time employment: Boehringer Ingelheim. W. Tang: Full / Part-time employment: Boehringer Ingelheim. D.C-L. Huang: Full / Part-time employment: Boehringer Ingelheim. A. Cseh: Full / Part-time employment: Boehringer Ingelheim. K. Park: Advisory / Consultancy: AMGEN; Advisory / Consultancy: Astellas; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy: BluePrint; Advisory / Consultancy: BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boehringer Ingelheim; Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: Hanmi; Advisory / Consultancy: KHK; Advisory / Consultancy: Loxo; Advisory / Consultancy: Merch KGaA; Advisory / Consultancy, Research grant / Funding (self): MSD; Advisory / Consultancy: ONO; Advisory / Consultancy: Roche. C. Zhou: Honoraria (self): BI; Honoraria (self): Roche; Honoraria (self): Sanofi; Honoraria (self): Hengrui; Honoraria (self): Qilu; Honoraria (self): MSD. Y-L. Wu: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Honoraria (self): Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Boehringer Ingelheim; Honoraria (self): Pfizer; Honoraria (self): Eli Lilly; Honoraria (self): MDS; Honoraria (self): BMS. All other authors have declared no conflicts of interest.
Resources from the same session
447P - Hypomagnesaemia: An unnoticed problem in lung cancer patients treated with concurrent chemoradiation
Presenter: Sharif Ahmed
Session: Poster display session
Resources:
Abstract
448P - Incidence and severity of chemotherapy induced peripheral neuropathy in geriatric population who are receiving chemotherapy
Presenter: Alekhya Mandepudi
Session: Poster display session
Resources:
Abstract
449P - Utility of screening tool for assessment of chemotherapy induced peripheral neuropathy in cancer patients
Presenter: PRUTHVI Paibhavi
Session: Poster display session
Resources:
Abstract
450P - Supportive care to control nausea and dizziness in malignant tumours: A systematic review
Presenter: Rainer Spiegel
Session: Poster display session
Resources:
Abstract
451P - The safety of ramucirumab without H1-antihistamines as a premedication in patients with solid cancers: A retrospective study
Presenter: Nobuhiro Hattori
Session: Poster display session
Resources:
Abstract
452P - Expression of erythropoietin receptor in patient with anemia related chemotherapy and its correlation with absolute reticulocyte count
Presenter: Irza Wahid
Session: Poster display session
Resources:
Abstract
453P - Body mass index did not correlate with short term overall survival in breast cancers
Presenter: Jungsun Lee
Session: Poster display session
Resources:
Abstract
454P - Predictors of severity and comparison of CTCAE V3.0 vs V4.3 in assessing chemotherapy induced extravasation injuries
Presenter: Sangana Reddy
Session: Poster display session
Resources:
Abstract
455P - Assessment of nutritional status and quality of life among cancer patients undergoing chemotherapy
Presenter: Sri Prathima
Session: Poster display session
Resources:
Abstract
456P - Use of gamma irradiated bone allografts in treatment of various bone tumours
Presenter: Anchal Mishra
Session: Poster display session
Resources:
Abstract